Syros unveils Phase 1 clinical trial data of SY-5609; cohort expanded
Category: #healthcare  By Akshay Kedari  Date: 2020-10-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Syros unveils Phase 1 clinical trial data of SY-5609; cohort expanded

Syros Pharmaceuticals has announced initial safety, pharmacodynamics (PD) and pharmacokinetics (PK) data from the current dose-escalation portion of Phase 1 clinical trial of SY-5609 in patients with select solid tumors.

For the starters, SY-5609 is a potent and highly selective oral cyclin-dependent kinase 7 (CDK7) inhibitor. The initial data—set to be revealed in a poster session at the 32nd EORTC-NCI-AACR Symposium—stage an MTD (maximum tolerated dose) for relentless daily dosing and serve as a “proof of mechanism” in patients with advanced solid tumors.

David A. Roth, M.D., Chief Medical Officer of Syros, is buoyed by the findings from Phase 1 trial of SY-5609 and claims that it reinforces their conviction in CDK7 inhibition as a likely transformative targeted approach for difficult-to-treat cancers.

Elaborating on the clinical trial, the Chief Medical Officer said they are “committed to fully exploring the potential of SY-5609.” He further noted that the trial was opened to pancreatic cancer patients; Syros expanded a cohort to emphasize lung cancer patients and further expanded the amalgamation cohort in treatment-resistant breast cancer patients.

In a bid to introduce optimal next steps meant for single-agent and providing the greatest services to patients, Syros has opened cohorts assessing alternate dosing regimens.

The Phase 1 clinical trial will continue to enroll patients with select solid tumors, such as the recently expanded single-agent cohort in lung cancer patients and combination cohort to assess the 3 mg daily dose in patient populations in breast cancer patients.

The trial is alleged to have opened to patients with advanced pancreatic cancer—a tumor that has exhibited sensitivity to SY-5609 in preclinical models.

Syros is slated to report additional dose-escalation data, including Clinical Activity Data in mid-2021. The company claims the safety profile of SY-5609, along with fulvestrant to be in line with single-agent SY-5609.

Source credit:

https://ir.syros.com/press-releases/detail/200/syros-presents-initial-data-from-phase-1-clinical-trial-of

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Robo-advisor startup Fount raises USD 33.4 million in Series C funding
Robo-advisor startup Fount raises USD 33.4 million in Series C funding
By Akshay Kedari

South Korea-based AI investment solution company Fount has reportedly raised USD 33.4 million in a S...

Mercedes-Benz India expects to cross 10,000 vehicle sales by year-end
Mercedes-Benz India expects to cross 10,000 vehicle sales by year-end
By Akshay Kedari

Demand for cars and after sales services has increased since the second half of June 2021. The co...

Reliance Retail to soon open 7-Eleven convenience stores across India
Reliance Retail to soon open 7-Eleven convenience stores across India
By Akshay Kedari

The retail arm of Reliance Industries, Reliance Retail Ventures Limited (RRVL), has recently signed ...